Examining the link between COPD and cognitive impairment
Determinants of Altered Brain Structure and Function in Smokers With COPD-Related Lung Pathophysiology
This study looks at how COPD might affect thinking and memory skills in people with early-stage COPD to see if we can find ways to help them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 275 (estimated) |
| Ages | 30 Years to 85 Years |
| Sex | All |
| Sponsor | University of Iowa Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT03269721 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how chronic obstructive pulmonary disease (COPD) affects brain function and contributes to cognitive impairment. It focuses on identifying pulmonary and vascular physiological mechanisms that lead to brain abnormalities in individuals with early-stage COPD. The study involves neuropsychological assessments, spirometry, and other tests to gather data on lung function and cognitive abilities. By understanding these connections, the research aims to inform future interventions to prevent or delay cognitive decline in COPD patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 30-85 with a history of smoking and early signs of COPD-related pathophysiology.
Not a fit: Patients with other significant respiratory disorders or major comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to strategies that help prevent cognitive dysfunction in patients with COPD.
How similar studies have performed: Other studies have shown promising results in understanding the relationship between COPD and cognitive impairment, indicating that this area of research is both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age 30-85, \> 8th grade education, Normal/corrected hearing and vision, English Speaker, Ability to comfortably lie flat for 1 hour. Exclusion Criteria: Other concomitant respiratory disorder other than asthma (e.g., cystic fibrosis), Use of antibiotics or steroids for a COPD exacerbation within the past month, Use of 24-hour oxygen, Pregnancy or suspected pregnancy, Uncontrolled cancer within the last 5 years, Radiation therapy to the chest, Lung surgery (LVRS, transplant, lobectomy), Lung cancer known or suspected, Eye surgery in the last 3 months, Pulmonary Hypertension, Insulin-dependent diabetes, Inability to use albuterol, Chest or abdominal surgery in the past 3 months, Heart attack in the last 3 months, Hospitalization for any heart problem in the past month, Prior neurological condition (e.g., stroke, epilepsy, head injury with \>15 mins. loss of consciousness), Previous diagnosis of dementia or learning disability, Major comorbid medical conditions with known cognitive effects (e.g., renal failure, HF), Psychotic disorder, bipolar disorder, current substance use disorder other than tobacco use, Change in psychiatric medication in last month, Claustrophobia, Metal object in body that may interfere with neuroimaging.
Where this trial is running
Iowa City, Iowa
- Carinda Linkenmeyer — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Principal investigator: Karin F Hoth, PhD — University of Iowa Department of Psychiatry
- Study coordinator: Tara Q Lanning, BS
- Email: tara-lanning@uiowa.edu
- Phone: 319-353-8520
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.